Adicet Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adicet Bio Inc (ACET) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adicet Bio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 39M vs 53,820M combined for its competitors (0.1% combined share).
- Scale: Adicet Bio Inc ranks #341 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.38M compares with $1.42M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Adicet Bio Inc vs. its Competitors, Q1 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Adicet Bio Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adicet Bio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adicet Bio Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adicet Bio Inc's competitor groups requires a Commercial License.
Adicet Bio Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adicet Bio Inc | - | - | - | Yes |
| Competitors combined (60) | ||||
| High-Confidence Competitors (15) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACET Stock Performance relative to its Competitors
ACET Stock Performance relative to High-Confidence Competitors
ACET Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 3 | Rallybio Corporation | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Immix Biopharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adicet Bio Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Adicet Bio Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Adicet Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Adicet Bio Inc |
32.77 | 38.70 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Madrigal Pharmaceuticals Inc |
12,114.04 | 1,427.94 |
 Nuvalent Inc |
9,751.98 | 4.23 |
 Rhythm Pharmaceuticals Inc |
7,752.49 | 280.75 |
 Merus N v |
6,810.81 | 56.61 |
| SUBTOTAL | 186,864.13 | 54,101.14 |
Sign in to see all competitors of Adicet Bio Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adicet Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adicet Bio Inc's Competitors Named by the Company
Competitive relationships identified from Adicet Bio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Allogene Therapeutics, Inc. | Company report | 85% |
| Century Therapeutics, Inc. | Company report | 85% |
| Novartis AG | Company report | 85% |
| Autolus Therapeutics | Company report | 85% |
| Legend Biotech | Company report | 85% |
| CRISPR Therapeutics AG | Company report | 85% |
| In8bio Inc | Company report | 85% |
| Bristol-Myers Squibb Company | Company report | 85% |
| Nkarta, Inc. | Company report | 85% |
| Fate Therapeutics, Inc. | Company report | 85% |
| Lava Therapeutics Nv | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| NAYA | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| INVO | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Immunogen inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Celyad Oncology Sa | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Adicet Bio Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Adicet Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
| Verastem Inc | Research Developing and Commercialization Drugs Segment 100.00 % |
| Xoma Royalty Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Adicet Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adicet Bio Inc | 33 | 379,422 | -1,066,990 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Madrigal Pharmaceuticals Inc | 12,114 | 1,560,590 | -169,905 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Rhythm Pharmaceuticals Inc | 7,752 | 678,135 | -476,599 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| PEERS TOTAL | 186,831 | 1,422,247 | 149,620 |
Adicet Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 69.43 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
| Durect Corp | Europe 72.48 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adicet Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Adicet Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Adicet Bio Inc ranks #341 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 341 | Adicet Bio Inc | 33 | 0.00 % |
Market cap and industry share for the rest of Adicet Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Adicet Bio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 336 | Crescent Biopharma Inc | 39 | 5.23 % |
| 337 | Aldeyra Therapeutics Inc | 38 | -87.41 % |
| 338 | Promis Neurosciences inc | 38 | -59.71 % |
| 339 | Kazia Therapeutics Limited | 38 | -5.92 % |
| 340 | Lite Strategy Inc | 1,234 | 12.3% |
| 341 | Adicet Bio Inc | 33 | -73.10 % |
| 342 | Grace Therapeutics Inc | 1,234 | 12.3% |
| 343 | Annovis Bio Inc | 1,234 | 12.3% |
| 344 | Intercure Ltd | 1,234 | 12.3% |
| 345 | Gridai Technologies Corp | 1,234 | 12.3% |
| 346 | Rockwell Medical inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Adicet Bio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Adicet Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 0.6x | 4.3x | -3.7x |
| Return on Equity | -80.35 % | industry aggregate | -97.16 % |
| Return on Invested Capital | -40.24 % | -9.83 % (avg) | -30.41 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adicet Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 35.53 % | -7.87 % | - | -99.89 % | 500.00 % | - | - | - |
| Operating Margin | 4.24 % | -46.03 % | - | 24,671.74 % | -631.38 % | - | - | - |
| Return on Invested Capital | 2.60 % | -63.68 % | -37.25 % | 47.78 % | -11.99 % | -33.46 % | -27.65 % | -41.53 % |
| P/E | - | - | - | 8.7x | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Adicet Bio Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Adicet Bio Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Adicet Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Adicet Bio Inc's dedicated Suppliers and Customers pages, not here.
Adicet Bio Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Adicet Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Adicet Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 97.2 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (62.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Adicet Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adicet Bio Inc | 1.83 | 7.06 | - |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Rhythm Pharmaceuticals Inc | 1.01 | 3.60 | 0.94 |
| Merus N v | 3.67 | 7.20 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adicet Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adicet Bio Inc | Q1 2026 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +79.6 % | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| PEERS TOTAL | +13.5 % | +120.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adicet Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adicet Bio Inc | Q1 2026 | - | -97.5 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +121.2 % | -98.8 % |
| Merus N v | Q3 2025 | - | +21.0 % |
Adicet Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adicet Bio Inc | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Rhythm Pharmaceuticals Inc | - | - | - |
| Merus N v | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adicet Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adicet Bio Inc | - | 0.85 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Madrigal Pharmaceuticals Inc | - | 8.48 |
| Nuvalent Inc | - | 2,303.80 |
| Rhythm Pharmaceuticals Inc | - | 27.61 |
| Merus N v | - | 120.32 |
| PEERS AVERAGE | 33.50 | 3.45 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.